Aim of the Study:This study was to analyze the clinical outcomes of brain stem glioma treated with radiation therapy (RT) in our institution.Material and Methods:Records of 48 patients with brainstem glioma treated between January 2007 and January 2013 were reviewed. Demographic variables, clinical variables, radiological findings and treatment details with respect to age, sex, location of tumor ( pontine Vs non pontine ), signs and symptoms, RT dose, follow up period and outcomes were recorded. Patients were subdivided into two groups based on their age, age <15 years (Group I) and age >=15 yrs (Group II).Results:The median age at diagnosis was 10 years (range 4-50). Male to female ratio was 11:10. Of the 48 cases analyzed, 27 patients (56%) were in group I and 21 (44%) were in group II. Radiologically, 90.5% had involvement of pons. 10 (21%) patients received RT dose >60 Gy and 38 (79 %) patients received RT dose of 54-60 Gy. Median overall survival was 7months (range 3-44 months). Median overall survival in Group I and Group II was 4 months and 10 months respectively (P = 0.042).Conclusions:Brain stem glioma in pediatric age group is associated with worse outcomes than in adults.

9055 Background: The purpose of this study was to compare the efficacy of a single fraction versus two multifractionated regimens in the palliation of painful bone metastases. Methods: Patients with painful bone metastases were randomized into three groups. Group I received a dose of 8 Gy in a single fraction, Group II received 20 Gy in five fractions and Group III patients received 30 Gy in 10 fractions. Pain score, ECOG performance status and analgesic requirement were recorded at baseline and at 1, 4, 8 and 12 weeks following treatment. Pain score was recorded on a 5-point verbal rating scale from 0 (no pain) to 4 (extremely severe pain). Overall response was defined as decrease in pain score by at least one point. Complete response was defined as achieving a pain score of zero at any point during follow-up. Duration of overall response was defined as the time from initial response till return of pain to its baseline value. Results: 45 patients were included with 15 in each group. Median age was 55 years (range 29-78 years). 17(37.7%) had metastasis in pelvic bones; 17(37.7%) in the spine while the remainder in the appendicular bones. Overall response rates in Groups I, II and III at week 1 were 60%, 53.3% and 60% respectively (p=0.71). At 1 month, overall response rates were 71.4%, 73.3% and 73.3% (p=0.84) and at 3 months; 78.5%, 80% and 80% respectively (p=0.86). The rate of complete response in all the three groups was 20%. Improvement in performance status in Groups I, II and III was seen in 60%, 66% and 80% respectively (p=0.69). Analgesic usage decreased in 86%, 87% and 80% patients in groups I, II and III respectively (p=0.66). Out of the nine complete responders, two sustained the response for less than four weeks, four patients up to eight weeks and remaining three till the end of follow-up. There was no statistically significant difference in between the three arms among all the variables compared. Conclusions: All three groups showed equal efficacy in pain palliation, analgesic requirement, improvement in performance status and duration of response. In patients with very advanced disease and short life expectancy, where the treatment goal is to decrease pain, 8 Gy in single fraction is a convenient and cost effective schedule.

e16545 Background: The standard of care in locally advanced carcinoma cervix is concurrent chemoradiotherapy. The aim of the study is to prospectively assess quality of life (QoL) in patients of carcinoma cervix treated with chemoradiotherapy. Methods: Between June 2011 and June 2012, 20 patients of carcinoma cervix were included in the study. All patients received conformal external beam radiotherapy (EBRT) on Linear accelerator to a total dose of 50Gy, 2 Gy per fraction, 25 fractions to the pelvis and intracavitary brachytherapy by High dose rate brachytherapy, 7 Gy per fraction, 3 fractions to a total dose of 21 Gy. Patients received concurrent chemotherapy with Cisplatin 40 mg/m2 weekly for five weeks. QoL was assessed using EORTC QLQ-C30 and QLQ-C24 questionnaires at baseline and at six months following completion of treatment. The collected data was analyzed using standard statistical software package (SPSS version 20.0). Results: Median age of the patients in the study was 52years ( range 34 – 69 years), 13 (65%) patients were stage II and seven (35%) were stage III. Mean duration of treatment is 37 days (range 34- 70 days). Local control rate at six months was 95%. Compliance with completion of QoL scores was high. A statistically significant improvement (p = 0.001) was seen at six months post treatment in Global health score and in function scales like physical function, role function, emotional function, social function and cognitive function. There was a significant improvement in symptom scales of urologic and vaginal symptoms. The difference in sexual function at six months showed a trend towards significance (p = 0.052). Conclusions: Patients of carcinoma cervix have a significant improvement in quality of life following treatment with radiotherapy and chemotherapy.

No abstract

e12501 Background: The standard of care for glioblastoma is surgical resection followed by adjuvant RT (radiotherapy) with concurrent and adjuvant temozolomide. Methods: Between January 2006 to December 2010, patients of glioblastoma who underwent surgery and RT to a dose of 60 Gy were analysed retrospectively. Age, KPS, extent of surgery, RPA class were noted and patients were divided into two groups, RT alone (Group I) or RT with concurrent temozolomide 75mg/m2/day followed by adjuvant temozolomide 150 mg/m2/dayX5days q28days for 6 cycles(Group II). Results: A total of 62 patients were analysed, 23 patients in group I and 39 in group II. Median age in group I was 48 years (range 16-60, 19 male, 4 female), 8(34.8%) patients underwent gross total resection, 12 (52.2%) had partial resection and 3(13%) had stereotactic biopsy. The median overall survival (OS) was six months. Median age in group II was 50 years (range 13-76, 26 male, 13 female), 17(43.6%) patients underwent gross total resection, 19(48.7%) had partial resection and 3 (7.7%) had stereotactic biopsy. The median OS was nine months (p=0.018). Patients were analysed according to the RPA class (III-VI). Median OS and 1 yr survival for group I for RPA class III,IV,V/ VI were 12, 6 and 4 months and 50%,15.3%,0% respectively. Median OS and 1 yr survival rates for group II for RPA class III, IV,V / VI were 20, 8 and 5.5 months and 66.6%, 35%, 30% respectively. On multivariate analysis age(p=0.005), KPS(p=0.05), extent of surgery(p=0.043) were found to affect survival. Conclusions: Concurrent radiotherapy and temozolomide followed by adjuvant temozolomide results in improved survival in glioblastoma.